Ixekizumab-induced interstitial lung disease: a case report confirmed by transbronchial lung cryobiopsy
Background: Ixekizumab, an interleukin-17A (IL-17A) inhibitor used in psoriasis treatment, has been linked to drug-induced interstitial lung disease (DI-ILD). The pathophysiological mechanisms and histopathological features of this adverse effect remain poorly documented.Case Presentation: A 69-year...
Saved in:
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2024-12-01
|
Series: | Journal of Dermatological Treatment |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2024.2424338 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|